Skip to main content
SpringerLink
Log in

CQ29. Is Chemotherapy Effective for Advanced or Relapsed Medullary Carcinoma?

  • Chapter
  • First Online:
Treatment of Thyroid Tumor

  • 1328 Accesses

Abstract

We studied the literature for the effectiveness of chemotherapy on advanced or relapsed medullary thyroid carcinoma with no indications for surgery, where tangible tumors were detectable on palpation or imaging studies. Serum cacitonin level and CEA level are sensitive tumor markers of medullary carcinoma and these elevations are often initial signs of recurrence before findings on imaging studies, but no reports are available for chemotherapy for cases without relapsed tumors for which sizes can be measured.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Petursson SR (1988) Metastatic medullary thyroid carcinoma: complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer 62:1899–1903 (CR)

    Article  PubMed  CAS  Google Scholar 

  2. Gottlieb JA, Hill CS Jr (1974) Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med 290:193–197 (RS)

    Article  PubMed  CAS  Google Scholar 

  3. Shimaoka K, Schoenfeld DA, DeWys WD et al (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155–2160 (RCT)

    Article  PubMed  CAS  Google Scholar 

  4. Scherübl H, Raue F, Ziegler R (1990) Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol 116:21–23 (PS)

    Article  PubMed  Google Scholar 

  5. Orlandi F, Caraci P, Berruti B et al (1994) Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol 5:763–765 (RS)

    PubMed  CAS  Google Scholar 

  6. Wu LT, Averbuch SD, Ball DW et al (1994) Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 73:432–436 (RS)

    Article  PubMed  CAS  Google Scholar 

  7. Schlumberger M, Abdelmoumene N, Delisle MJ et al (1995) Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. Br J Cancer 71:363–365 (unknown study design)

    Article  PubMed  CAS  Google Scholar 

  8. Nocera M, Baudin E, Pellegriti G et al (2000) Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Br J Cancer 83:715–718 (RS)

    Article  PubMed  CAS  Google Scholar 

  9. Matuszczyk A, Petersenn S, Bockisch A et al (2008) Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 40:210–213 (RS)

    Article  PubMed  CAS  Google Scholar 

  10. Lorenz K, Brauckhoff M, Behrmann C et al (2005) Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. Surgery 138:986–993 (PS)

    Article  PubMed  Google Scholar 

  11. Fromigué J, De Baere T, Baudin E et al (2006) Chemoembolization for liver metastases from medullary thryoid carcinoma. J Clin Endocrinol Metab 91:2496–2499 (PS)

    Article  PubMed  Google Scholar 

  12. Lupoli G, Cascone E, Arlotta F et al (1996) Treatment of advanced medullary thyroid carcinoma with a combination of recombiant interferon alpha-2b and octreotide. Cancer 78:1114–1118 (RS)

    Article  PubMed  CAS  Google Scholar 

  13. Mahler C, Verhelst J, De Longueville M et al (1990) Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol 33:261–269 (RS)

    Article  CAS  Google Scholar 

  14. Modigliani E, Cohen R, Joannidis S et al (1992) Results of long-term continuous subcutaneous ocreotide administration in 14 patients with medullary thyroid carcinoma. Clin Endocrinol 36:183–186 (RS)

    Article  CAS  Google Scholar 

  15. Diez JJ, Iglesias P (2002) Somatostatin analogs in the treatment of medullary thyroid carcinoma. J Endocrinol Invest 25:773–778 (RS)

    PubMed  CAS  Google Scholar 

  16. Vitale G, Tagliaferri P, Caraglia M et al (2000) Slow release lanreotide in combination with interferon-alpha 2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 85:983–988 (unknown study design)

    Article  PubMed  CAS  Google Scholar 

  17. British Thyroid Associations & Royal College of Physicians (2007) Guidelines for the management of thyroid cancer in adults, 2nd edn. www.british-thyroid-association.org

  18. Cooper DS, Doherty GM, Haugen BR et al (2006) American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109–142, http://www.thyroid.org/professionals/publications/documents/Guidelinesthy2006.pdf

    Article  PubMed  Google Scholar 

  19. NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma (2009) v1. http://www.nccn.org/professionals/physician_gls/PDF/thyroid.pdf

  20. Kloos RT, Eng C, Evans DB et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565–612, http://www.thyroid.org/professionals/publications/documents/MTC_Guidelines.pdf

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Noguchi Thyroid Clinic and Hospital Foundation, 6-33 Noguchinakamachi, Beppu, Oita, 874-0932, Japan

    Shinya Uchino

  2. Department of Breast and Endocrine Surgery, Toranomon Hospital, Tokyo, Japan

    Daishu Miura

  3. Department of Endocrine Surgery and Hygiene & Public Health II, Tokyo Women’s Medical University, Tokyo, Japan

    Takahiro Okamoto

Authors
  1. Shinya Uchino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daishu Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takahiro Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shinya Uchino .

Editor information

Editors and Affiliations

  1. Ito Hospital, 4-3-6 Jinguumae, Shibuya-ku, Tokyo, 150-8308, Japan

    Hiroshi Takami

  2. , Department of Surgery, Kuma Hospital, 8-2-35 Shimoyamate-dori, Chuo-ku, Kobe, 650-0011, Japan

    Yasuhiro Ito

  3. Noguchi Thyroid Clinic and Hospital Foun, 6-33 Noguchinaka-machi, Beppu, 874-0932, Japan

    Hitoshi Noguchi

  4. , Department of Breast and Endocrine Surge, Kanagawa Cancer Center, 1-1-2 Nakao, Asahi-ku, Yokohama, 241-8515, Japan

    Akira Yoshida

  5. , Department of Endocrine Surgery, Tokyo Women's Medical University, 8-1 Kawada- cho, Shinjuku-ku, Tokyo, 162-8666, Japan

    Takahiro Okamoto

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Japan

About this chapter

Cite this chapter

Uchino, S., Miura, D., Okamoto, T. (2013). CQ29. Is Chemotherapy Effective for Advanced or Relapsed Medullary Carcinoma?. In: Takami, H., Ito, Y., Noguchi, H., Yoshida, A., Okamoto, T. (eds) Treatment of Thyroid Tumor. Springer, Tokyo. https://doi.org/10.1007/978-4-431-54049-6_40

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-54049-6_40

  • Published:

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-54048-9

  • Online ISBN: 978-4-431-54049-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation